অগ্ন্যাশয় ক্যান্সার প্রতিরোধের আক্রমণ বন্ধ করতে সংকেত প্রেরণ করে – ফিউচারিটি: রিসার্চ নিউজ

অগ্ন্যাশয় ক্যান্সার প্রতিরোধের আক্রমণ বন্ধ করতে সংকেত প্রেরণ করে – ফিউচারিটি: রিসার্চ নিউজ


Translating…

A key immune signal has a previously unknown role in turning off the immune system’s attack on pancreatic cancer cells, a new study finds.

The researchers found that pancreatic tumor cells make and release an immune signaling protein, interleukin-1β (IL-1β). This was shown to reduce anticancer immune responses, which promoted the growth of pancreatic ductal adenocarcinoma or PDA, a form of cancer that is usually deadly within two years.

The study in Cancer Research shows that blocking the action of IL-1β in mice with immune proteins called antibodies caused a 32% decrease in PDA tumor growth.

Pancreatic cancer and immune “checkpoints”

Other experiments combined the anti-IL-1β antibody, which gloms onto and neutralizes its target, with an already approved antibody treatment that shuts down the protein “checkpoint” called PD1. To spare normal cells from immune attack, the immune system uses “checkpoints” on immune cells that turn them off when they receive the right signal. Cancer cells hijack checkpoints to turn off the system, leading to immune suppression of CD8+ T cells that would otherwise kill cancer cells. Therapies called checkpoint inhibitors counter this effect.

While effective against many cancers, checkpoint inhibitors have failed in PDA, with the response rate in tumors as low as roughly three percent in some trials, and the limitations attributed to poor CD8+ T cell infiltration and immune suppression. In the current study, adding anti-IL-1β antibodies to anti-PD-1 antibody treatment doubled the infiltration of such T cells into PDA tumors and increased the antitumor activity of PD-1 blockade by 40%.

“By engineering mice with versions of PDA that lack the IL-1β gene, we found for the first time that pancreatic cancer cells produce IL-1β, and that it is essential for the continued growth of PDA tumors,” says study senior author Dafna Bar-Sagi, vice dean for science and chief science officer for New York University’s Langone Health.

“Blocking IL-1β with an antibody treatment may represent another way to make pancreatic tumors vulnerable to the immune system, with the potential to significantly increase the effectiveness of checkpoint inhibitors if combined,” Bar-Sagi says.

A new strategy to fight cancer?

The new finding is in line with past work in other labs that described the microbiome, the mix of bacterial species in the pancreas, as being altered in the presence of PDA, and a factor in cancer growth. The field had traditionally assigned the production of IL-1β to immune cells, but the new work finds that pancreatic tumor cells can also make it in response to proteins certain bacteria give off.

Researchers found that bacterial products activated proteins on the cancer cell surfaces called toll-like receptors, which set off chain reactions required for IL-1β production in cancer cells.

The research team also found that higher IL-1β production caused nearby pancreatic stellate cells to increase production of dense, structural proteins like collagen. Desmoplasia is the overgrowth of such fibrous tissue that often occurs near pancreatic tumors, and which has been linked to treatment resistance.

Researchers also found that active stellate cells trigger production of the signaling proteins that attract immune cells called macrophages into tumors and programs them to become the type (M2) that suppresses immune reactions. Experiments also confirmed that higher IL-1β and M2 macrophage levels, along with fibroblast-driven desmoplasia, reduced the ability of cancer-cell-killing CD8+ T cells to enter tumors.

“This work provides strong evidence that blocking the action of IL-1β enables T cells to better penetrate tumors and kill cancer cells, mechanisms with potential to overcome the limitation of currently available immunotherapies in the treatment of pancreatic cancer,” says first author Shipra Das, who was a member of Bar-Sagi’s lab at the time the study was done.

While no study author received financial compensation, the pharmaceutical company Novartis provided the mouse anti-PD1 and anti-IL-1β antibodies for this study.

Support for the work came from the National Institutes of Health, the Lustgarten Foundation Pancreatic Cancer Convergence Dream Team, Stand Up To Cancer, the Entertainment Industry Foundation, American Association for Cancer Research, and the Canadian Institutes of Health Research.

Source: NYU